Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors  by Conde, Sofia et al.
ON
l
S
A
a
b
a
A
R
R
2
A
K
R
N
c
N
c
P
A
1
R
o
1
hreports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 67–75
Available  online  at  www.sciencedirect.com
jou rn al h om epa ge: ht tp : / /www.e lsev ier .com/ locate / rpor
riginal research article
eoadjuvant  oral  vs.  infusional  chemoradiotherapy  on
ocally advanced  rectal  cancer:  Prognostic  factors
oﬁa Condea,∗, Margarida Borregoa, Tânia Teixeiraa, Rubina Teixeiraa,
nabela  Sáb, Paula Soaresa
Radiotherapy Department, Hospitais da Universidade de Coimbra, Portugal
Oncology Department, Hospitais da Universidade de Coimbra, Portugal
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 20 April 2011
eceived in revised form
4  May 2012
ccepted 13 July 2012
eywords:
ectal cancer
eoadjuvant oral
hemoradiotherapy
eoadjuvant infusional
hemoradiotherapy
rognostic factors
djuvant chemotherapy
a  b  s  t  r  a  c  t
Aim: To evaluate the prognostic factors and impact on survival of neoadjuvant oral and
infusional chemoradiotherapy in patients with locally advanced rectal cancer.
Background: There is still no deﬁnitive consensus about the prognostic factors and the impact
of  neoadjuvant chemoradiotherapy on survival. Some studies have pointed to an improve-
ment in overall survival (OS) and progression-free survival (PFS) in patients with tumor
downstaging (TD) and nodal downstaging (ND).
Materials and methods: A set of 159 patients with LARC were treated preoperatively. Group A –
112  patients underwent concomitant oral chemoradiotherapy: capecitabine or UFT + folinic
acid. Group B – 47 patients submitted to concomitant chemoradiation with 5-FU in contin-
uous infusion. 63.6% of patients were submitted to adjuvant chemotherapy.
Results: Group A: pathologic complete response (pCR) – 18.7%; TD – 55.1%; ND – 76%; loco-
regional response – 74.8%. Group B: pCR – 11.4%; TD – 50%; ND – 55.8%; LRR – 54.5%. The
loco-regional control was 95.6%. There was no difference in survival between both groups.
Those with loco-regional response had better PFS.
Conclusions: Tumor and nodal downstaging, loco-regional response and a normal CEA level
turned out to be important prognostic factors in locally advanced rectal cancer. Nodal down-
staging and loco-regional response were higher in Group A. Those with tumor downstagingand  loco-regional response from Group A had better OS. Adjuvant chemotherapy had no
impact on survival except in those patients with loco-regional response who achieved a
higher PFS.
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therapy (RT) reduce the rate of local relapse and prolong.  Backgroundectal adenocarcinoma is associated with a very high rate
f local relapse after surgery alone. Some studies have
∗ Corresponding author at: Hospitais da Universidade de Coimbra; Prac
E-mail  address: sofconde@hotmail.com (S. Conde).
507-1367/$ – see front matter © 2012 Greater Poland Cancer Centre. Publish
ttp://dx.doi.org/10.1016/j.rpor.2012.07.010rights reserved.
demonstrated that adjuvant chemotherapy (CT) and radio-eta Prof. Mota Pinto, Portugal. Tel.: +351 919 212 230.
survival in patients whose tumors extend into the perirec-
tal fat (T3) or who have mesorectal or pelvic lymph nodes
involvement (N1–3).1
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Patients were scheduled for surgery between the sixth and
eighth week following the conclusion of the neoadjuvant ther-
apy and were treated with a total mesorectum excision.68  reports of practical oncology a
Preoperative chemoradiotherapy (CT + RT) offers some the-
oretical advantages over adjuvant therapy for patients with
a tumor of the middle to lower rectum2: (i) micrometastases
are treated early in the course of the disease; (ii) the risk of
tumor seeding during surgery is reduced; (iii) RT toxicity is
also reduced; (iv) the efﬁcacy of CT and RT is higher in a tumor
with an intact vasculature; (v) if the tumor shrinks, a sphinc-
ter preserving procedure can be performed. Nevertheless, this
treatment also has some drawbacks: (i) deﬁnitive therapy is
delayed, which may allow the growth and dissemination of the
tumor; (ii) as preoperative staging is not very precise, patients
on early stages (T1–2N0) of the disease, who do not need this
therapy because of their very low risk of relapse, would be
overtreated.
After the randomized trial CAO/ARO/AIO,3 neoadjuvant
CT + RT became the standard of care, since the 5-year
local recurrence rate is reduced, adherence is better and
it has fewer acute and long-term toxic effects than post-
operative CT + RT. Neoadjuvant use of CT and RT allows a
higher rate of resectability associated to a tumor and nodal
downstaging.4
Concomitant neoadjuvant 5-FU CT + RT provides a patho-
logic complete response (pCR) in 8–27% of cases and is
associated with an increased local control.2–14 The single ran-
domized trial that compared preoperative vs. postoperative
CT + RT concluded that there was a lower 5-year local relapse
(6% vs. 13%, p = 0.006) and a decrease in acute and late toxicity
with preoperative CT + RT, although there was no difference
in overall survival.3 Theoretically, oral ﬂuoropyrimidines are
suitable to replace protracted infusion of 5-FU and avoid more
invasive procedures.
Elevated preoperative serum carcinoembryonic antigen
(CEA) levels, the most widely used tumor marker for the
management of colorectal cancer, has been reported to be
associated with a pathologic complete response, tumor down-
staging and with an increased risk of relapse and poor patient
outcome.15–17
The impact of neoadjuvant CT + RT on survival has been
controversial. Some studies have pointed to an improve-
ment in overall survival (OS) and progression-free survival
(PFS) in patients with pathological response after neoadjuvant
therapy.9,18,19
2.  Aim
Since the standard schedule of preoperative CT + RT for rectal
cancer remains to be established, and due to the conve-
nience of oral drugs, we evaluate the therapeutic response
to 5-FU and oral chemotherapy either with UFT and folinic
acid or capecitabine combined with preoperative RT in
patients with stages II–III rectal cancer in order to estab-
lish the best regimen for neoadjuvant treatment. Toxicity
and survival were also analyzed for both groups, as well as
the relationship between pathologic response, tumor down-
staging, nodal downstaging and loco-regional response and
survival. We  analyze the impact of adjuvant chemother-
apy in these patients, as this has also been a controversial
issue.20,21diotherapy 1 8 ( 2 0 1 3 ) 67–75
3.  Materials  and  methods
3.1.  Patients
We analyzed prospectively 159 patients with locally advanced
rectal cancer (LARC) treated with neoadjuvant chemoradio-
therapy from December 2002 to September 2009. We included
all patients with endoscopic and/or radiologic tumors staged
as II–III rectal cancer from our Institution, without associ-
ated co-morbidities that preclude the proposed therapy and
group selection was done according to the ability to adhere
to oral therapy. Patients were divided into 2 groups. Group A:
consisting of 112 patients who were treated with RT and con-
comitant oral CT. Group B: consisting of 47 patients, submitted
to RT and concomitant CT with continuous infusion of 5-FU.
Patients’ characteristics corresponding to the different groups
are described in Table 1.
3.2. Neoadjuvant  radiotherapy
The patient’s prone position was recommended, and a belly
board immobilization device was used. A pelvic CT scan in
the treatment position was performed in all patients, from
L5-S1 to 2 cm distal to the anus. All patients underwent
three-dimensional treatment planning. CT scan was used to
deﬁne gross tumor volume (GTV). Clinical target volume (CTV)
included the GTV + 2 cm in all directions, perirectal, internal
iliac and presacral nodes up to the promontory; for T4 (seminal
vesicles, prostate, vagina or uterus involvement) external iliac
nodes were also included; the inguinal areas were irradiated
in those patients who had invasion of the anal canal.22,23
The planning target volume (PTV) was deﬁned as
CTV + 1 cm margin. The treatment was delivered through
three to four ﬁelds via the isocenter technique, shaped with
multileaf collimator, and high-energy photons of 18 MV. The
total dose administered was 50.4 Gy with conventional frac-
tionation of 1.8 Gy/d, ﬁve days per week. The prescribed dose
was speciﬁed at the International Commission on Radiation
Units and Measurements point and isodose distribution to the
PTV (95% to 107%).
3.3.  Neoadjuvant  chemotherapy
Group A was treated with oral CT concomitant to RT, including
capecitabine or UFT. The capecitabine subgroup (61 patients)
received an oral 825 mg/m2 dose twice daily for the dura-
tion of RT (Monday–Sunday, including technical breaks). the
UFT subgroup received a dose of 300 mg/m2/d of UFT together
with folinic acid 90 mg/d (51 patients), in three fractions/d,
5 days/week (Monday–Friday, with the weekend as a rest
period). Group B was treated with RT concomitant to infu-
sional CT and 5-FU was administered at a dose of 225 mg/m2/d
in a continuous infusion, 7 days/week.
3.4.  Surgery
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Table 1 – Patients’ characteristics and surgical status.
Patients’ characteristics Group A (n = 112)
RT + oral CT
Group B (n = 47)
RT + infusional CT
p Value
Age (years)
Min–max 35–82 20–81
Median 64 61
Sex
Male 75 (67%) 26 (55.3%)
0.206
Female 37 (33%) 21 (44.7%)
Karnofsky
100% 73 (65.2%) 30 (63.8%)
0.97390% 35 (31.2%) 15 (31.9%)
80% 4 (3.6%) 2  (4.3%)
Distance to anal margin
0–5  cm 64 (57.1%) 22 (46.8%)
0.296
6–11 cm 48 (42.9%) 25 (53.2%)
Imaging staging (CT/MRI scan) 12.5/86.6% 0/100% 0.031
Clinical staging
cT2  11 (9.8%) 5 (10.6%)
0.001cT3 92 (82.1%) 30 (63.8%)
cT4 9 (8.0%) 12 (25.5%)
cN0 11 (9.8%) 1 (2.1%)
0.112
cN+ 101 (90.2%) 46 (97.9%)
CEA
<5.4 73 (67.6%) 30 (63.8%)
0.112≥5.4 35 (32.4%) 17 (36.2%)
CA 19.9
<37  93 (84.5%) 40 (85.1%)
1.0≥37 17 (15.5%) 7 (14.9%)
Timing to surgery (median) 7 weeks 7 weeks
Surgery
RAR 62 (55.4%) 26 (56.5%)
APR 45 (40.2%) 19 (41.3%) 0.550
Unresectable 4 (3.6%) 1  (2.2%)
Non operated 1  (0.9%) 1 (2.2%)
Surgical resection
R0  98 (87.5%) 42 (91.3%)
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ARR: rectal anterior resection; APR: abdomino-perineal resection.
.5.  Toxicity  assessment
oxicity was evaluated weekly in each patient using common
erminology criteria for adverse events vs. 3.0 (CTCAE).24 A
omplete blood count and biochemical tests were obtained
eekly.
.6.  Deﬁnition  of  response
valuation of response to preoperative treatment was deﬁned
athologically. Resected tumors were classiﬁed pathologically
ccording to the TNM staging system, version 6.25 Tumor
ownstaging was deﬁned as postoperative ypT stage lower
han preradiotherapy clinical cT stage. Nodal downstaging
as deﬁned as postoperative ypN stage lower than preradio-
herapy clinical cN stage. Loco-regional response was deﬁned
s a downstaging from cTN to pTN. A pathologic complete
esponse (pCR) was considered when there were no residual
alignant cells.
.7. Adjuvant  treatment
fter surgery, adjuvant CT was given to patients who
ere considered by the treating physician to potentially
eneﬁt from postoperative therapy (96 patients). The pro-
ocols of adjuvant CT used were FOLFOX (21.9%), CAPOX
10.4%), De Gramont (bolus 5-FU, infusional 5-FU and folinic
cid) in 11.4% patients, capecitabine (25%), UFT (28.1%) or
thers (3.1%).2 (4.3%)
3.8.  Follow-up
Following the conclusion of treatment, patients had outpa-
tient clinic appointments every 3 months for the ﬁrst 2 years,
and then every 6 months.
3.9.  Patterns-of-failure  analysis  and  survival
Loco-regional failure was deﬁned as a relapse in the pelvis
(tumor bed, pelvic nodes, anastomosis, or perineal scar). Fail-
ure at distance was deﬁned as relapse in any other site. OS,
PFS, and loco-regional control (LRC) were calculated from the
date of beginning of treatment.
3.10.  Statistical  considerations
Statistical analyses were performed using the SPSS 16.0 sta-
tistical package. The p-value was calculated by the chi-square
test to compare variables. OS, PFS and LRC probabilities were
calculated by the Kaplan–Meier method, and differences were
evaluated by the log–rank test. A two-sided p-value of <0.05
was considered statistically signiﬁcant.
4.  Results
4.1.  Toxicity  and  treatment  adherence4.1.1. Preoperative  treatment
Overall, preoperative therapies were well tolerated and the
most commonly reported events are shown in Table 2. Group A
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Table 2 – Neoadjuvant chemoradiotherapy acute toxicities incidence. CTCAE (v. 3.0).
Acute toxicity (%) Group A Group B
Grades 1–2 Grade 3 Grade 4 Grades 1–2 Grade 3
Diarrhea 27.7 4.5 0.9 23.9  6.5
Vomiting 3.6 4.3 2.2
Radiodermitis 54.5 4.5 54.3
4.3
4.3  2.2
2.2
Table 3 – Adjuvant CT acute toxicities incidence.
CTCAE (v. 3.0) Adjuvant CT toxicities
Grades 1–2 Grades 3–4
Diarrhea 1 (1%) 6 (6.2%)
Vomiting 3 (3.1%) 2 (2.1%)
Nausea 5 (5.2%) 1 (1%)
Anemia 36 (37.5%) 1 (1%)
Neutropenia 22 (22.9%) 3 (3.1%)
Thrombocytopenia 21 (21.9%) –
Paresthesia 19 (19.8%) 1 (1%)
Hand–foot synd. 2 (2.1%) 6 (6.2%)
Weight loss 1 (1%) –
Bilirrubin – 1 (1%)
Transaminases 3 (3.1%) –
Renal 1 (1%) 2 (2.1%)
Asthenia 4 (4.2%) –
Anorexia 1 (1%) –
Table 4 – Therapeutic response to neoadjuvant
treatment.
Group A
n = 107
Group B
n = 44
p Value
Tumor downstaging 55.1% 50% 0.594
Tumor downstaging to
ypT0-2, considering
only cT3-4 patients
51%  41% 0.344
Nodal downstaging 76% 55.8% 0.027
Loco-regional response 74.8% 54.5% 0.020Hand–foot synd. 6.3 
Haematologic 13.4 1.8
Others 12.5 
presented acute toxicity in 80.4% of patients, but only 11 (9.8%)
were grades 3–4. GROUP B showed an acute toxicity in 65.2%
of patients, of whom 5 (10.9%) were grades 3–4. One patient
has not completed treatment due to allergic reaction to 5-FU
and was excluded from this analysis.
There was a trend to a higher acute toxicity proﬁle on Group
A (p = 0.064), however, if we only compare grades 3–4 acute
toxicity, there was no signiﬁcant difference (p = 0.781) among
the two groups.
4.1.2.  AT  surgery
The median time interval between the end of RT and surgery
was 7 weeks. A complete resection was done in the majority
of patients undergoing CT + RT. Four patients from GROUP A
and one patient from Group B were considered unresectable.
One patient was not operated due to disease progression and
another by intercurrent illness (Table 1).
There was no statistical difference in postoperative com-
plications between the two groups (42.1% vs. 31.8%; p = 0.274).
The main postoperative complications in Groups A and B were,
respectively, surgical wound infections (23.4% vs. 6.8%), ﬁs-
tula (4.7% vs. 9.1%), suture dehiscence (10.3% vs. 4.5%) and
sub-occlusive disease (5.6% vs. 2.3%). Two patients died post-
operatively due to pulmonary thromboembolism.
4.1.3.  Postoperative  treatment
Of the 151 patients submitted to radical surgery and who
were candidates for adjuvant CT, only 63.6% received the pro-
posed treatment (64 patients from Group A and 32 patients
from Group B). Acute toxicity was reported in 65.6% of
patients undergoing adjuvant CT. The respective toxicities are
described in Table 3.
The main reason why the majority of the 55 patients did not
receive adjuvant CT was postoperative complications (60%),
16.4% of patients did not undergo adjuvant CT because of pCR
and pT2N0M0, 7.2% due to disease progression, 3.6% were not
referred to the oncologist and 1.8% because of poor PS (ECOG
3).
4.2.  Treatment  response
Nodal downstaging (p = 0.027) and loco-regional response
(p = 0.020) were higher in patients treated with oral CT + RT.
Although there was no statistical signiﬁcance, pCR and tumor
downstaging to ypT0-2 rates were higher in patients treated
with preoperative oral CT + RT (p = 0.340 and p = 0.344, respec-
tively). Tumor downstaging was equal in both groups (Table 4).
When we  analyzed the impact of the initial tumoral mark-
ers’ level on treatment response, we  veriﬁed that patientsPathologic complete
response
18.7%  11.4% 0.340
with higher levels of CEA (≥5.4 ng/ml) and CA 19.9 (≥37 ng/ml)
had worse rates of tumor downstaging to ypT0-2 (p = 0.045
and p = 0.013, respectively). Pretreatment CEA and CA 19.9 lev-
els did not have any impact on nodal downstaging (p = 0.557
and p = 0.122, respectively), pCR (p = 0.144 and p = 0.201, respec-
tively) nor on loco-regional response (p = 0.347 and p = 0.121,
respectively).
The median follow-up time was 34 months (4–91 months).
The LRC was 95.6%. Of those 6 patients who had locoregional
recurrence, 2 were submitted to an R1 resection, 3 had distant
recurrence, 1 had interrupted RT due to sub-occlusive disease
and 4 had initial tumoral markers elevated. The global 5-year
PFS was 70.3%. The global 5-year OS was 74.2%.
When we  analyzed the impact of response to neoadju-
vant therapy and initial tumoral markers’ status on survival
(Table 5), we found that patients with tumor downstaging,
nodal downstaging, loco-regional response or normal initial
CEA level (<5.4 ng/ml) had better OS and PFS. Those with tumor
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Table 5 – Impact of prognostic factors on survival.
OS PFS LRC
5-year p Value 5-year p Value 5-year p Value
Tumor downstaging 82.4%
0.035
81.0%
0.041
100%
0.007
No tumor downstaging 65.7% 59.3% 90.5%
Tumor downstaging to ypT0-2,
considering only cT3-4 patients
82.5%
0.016
84.0%
0.005
100%
0.014
No tumor downstaging to ypT0-2,
considering only cT3-4 patients
64.0%  53.8% 90.3%
Nodal downstaging 75.0%
0.050
75.4%
0.009
95.7%
0.852
No nodal downstaging 60.8% 45.7% 93.9%
Loco-regional response 77.1%
0.095
77.3%
0.024
96%
0.897
No loco-regional response 67.2% 55.3% 94.7%
Pathologic complete response 90.0%
0.068
90.7%
0.120
100%
0.272
No pathologic complete response 71.2% 66.2% 94.8%
Elevated initial CEA 61.6%
0.007
54.4%
0.027
93.4%
0.284
Normal initial CEA 78%  75.6% 96.7%
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ownstaging or normal initial CA 19.9 tumoral marker levels
<37 ng/ml) had a higher LRC.
Comparing Group A and Group B, we realized that there
as no difference in 5-year OS (80.5% vs. 62.2%, p = 0.186), PFS
71.5% vs. 65.6%, p = 0.861) nor in LRC (94.7% vs. 97.6%, p = 0.448,
espectively). If we only consider those patients who had loco-
egional response, those who  were submitted to oral CT + RT
ad better 5-year OS than those who had undergone infusional
T + RT (84.8% vs. 58.3%, respectively, p = 0.05). When we ana-
yzed those patients with tumor downstaging we also veriﬁed
 higher 5-year OS in patients from Group A (92% vs. 69.5%,
espectively, p = 0.039). It was veriﬁed a trend to a higher OS
n patients who  had nodal downstaging and undergone oral
T + RT (82.9% vs. 58.3%, p = 0.090). The type of combined treat-
ent prescribed did not have any impact on survival in those
atients who  had a pathologic complete response.
The addition of adjuvant CT did not add a beneﬁt on 5-
ear LRC (96.5% vs. 94%, p = 0.433), on 5-year PFS (70.1% vs.
5.9%, p = 0.188) nor on 5-year OS (71.4% vs. 75.5%, p = 0.749).
f we  only take into account those patients who had loco-
egional response, there was a beneﬁt on 5-year PFS in those
ho  received adjuvant CT (81.7% vs. 67.6%, p = 0.05).
For those patients cT3-4 who  had pathologic downstaging
o ypT0-2 the OS, PFS and LRC were similar to those who were
ubmitted or not to adjuvant CT (p = 0.404, p = 0.554 and p = 1.0,
espectively). In those patients who had no pathologic down-
taging (ypT3-4) and were or were not treated with adjuvant
T, there was also no evidence of beneﬁt on OS, PFS nor on
RC (p = 0.502, p = 0.208 and p = 0.515, respectively).
. Discussion  and  conclusionshe factors which predict the response to neoadjuvant
hemoradiotherapy in rectal cancer have not been well67.5%
0.604
84.4%
0.005
70.3% 97.4%
characterized. Their knowledge might be useful to clinicians
and patients for predicting treatment outcomes and, hence,
for making treatment decisions. A better understanding of
predictive factors may eventually lead to the development
of risk-adapted treatment strategies, such as more  aggres-
sive preoperative regimens, in patients who are less likely
to respond to standard preoperative therapy. Hence, we  per-
formed this single-institution prospective study, the ﬁrst of
this kind in our country.
Neoadjuvant pelvic RT combined with CT should be
regarded as a standard treatment for stage II and III rectal can-
cer and, although there is an increase in acute toxicity, it does
not alter the treatment compliance.26
Preoperative CT + RT can lead to tumor downstaging and
improves resectability in LARC.27,28 Continuous i.v. 5-FU infu-
sion is superior to 5-FU bolus in terms of tumor response,
and it is associated to a slight increase in OS and LRC in
advanced colorectal cancer.29,30 Although continuous i.v. infu-
sion has the biologic advantage of prolonging the exposure
of cells to 5-FU and improving antitumor activity, its disad-
vantages include the requirement of a central venous access
with potential complications, such as bleeding, thrombosis
and pneumothorax.31 Oral CT mimics the pharmacokinetics
of continuous 5-FU infusion, with elevated and maintained
concentrations of 5-FU for a prolonged period and higher
peak levels of 5-FU. It also avoids technical barriers of i.v.
infusion with the advantage of convenience. Therefore, oral
ﬂuoropyrimidines, UFT and capecitabine, constitute an attrac-
tive alternative.
The most commonly reported early endpoint is the rate
of pCR. It appears to be associated in some non random-
ized studies with improvement in PFS.9,32 It has been shown
in one randomized trial that time interval between RT and
surgery inﬂuences the degree of downstaging, with 10%
of patients operated within 2 weeks of RT experiencing
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Table 6 – Neoadjuvant chemoradiotherapy results (2–14).
Authors No. RT CT Downstaging T (%) Downstaging N (%) pCR (%)
De Paoli et al.5 53 50.4 C 57 78 24
Krishnan et al.6 54 52.5 C 51 52 18
Kim et al.7 95 50.4 C 57 69 12
De la Torre et al.8
77
45–50.4
5-FU 43.3 25 13.2
78 UFT,L 59.2 23.7 13.2
Feliu et al.2 41 50.4 UFT,L 61 – 15
Janjan et al.9 117 45 5FU 62 – 27
NSABP R-0310 58 50.4 5FU,L – – 8
Sauer et al.3 421 50.4 5FU – – 8
Kim et al.11
145
50.4
5FU,L – –  11.3
133 C – – 16.1
Crane et al.12
207
45
5FU 62 – 23
196 – 42 – 5
Gerard et al.13
FFCD 9203
375
45
5FU,L  – – 11.4
367 – – – 3.6
Bosset et al.4
EORTC 22921
473
45
5FU,L  – – 13.7
476 – – – 5.3
14Fernandez-Martos et al. 94 45 UFT 
C: capecitabine; L: leucovorin.
pathological downstaging compared to 26% of patients oper-
ated 6–8 weeks after RT (p = 0.005).33 Many  studies have shown
that neoadjuvant CT + RT signiﬁcantly increases the rate of
pCR, as well as nodal and tumor downstaging (Table 6). How-
ever, there are few studies analyzing the impact of response
to neoadjuvant CT + RT on survival.
In our study, nodal downstaging (p = 0.027) and loco-
regional response (p = 0.020) were signiﬁcantly better in Group
A. The pCR was higher in Group A (18.7%) than in Group B
(11.4%), although it was not statistically signiﬁcant (p = 0.340).
The tumor downstaging was similar in both groups (55.1% and
50%, respectively). All these results are comparable to those
described in several studies.2–14
The role of tumor markers, CEA and CA19.9, in rectal can-
cer is still in debate. In 2006, Park et al. showed that elevated
pretreatment CEA levels (>5ng/ml) were associated with poor
tumor response to preoperative chemoradiation.17 Das et al.34
concluded that CEA level (>2.5 ng/ml) resulted in signiﬁcantly
lower pCR rates (p = 0.015).
We  veriﬁed that those patients with higher pretreatment
levels of CEA and CA 19.9 showed lower rates of tumor
downstaging to ypT0-2 (p = 0.045 and p = 0.013, respectively).
Nevertheless, the relationship between pretreatment CEA and
CA 19.9 levels and pCR was not statistically signiﬁcant.
When we  analyzed the impact of response to neoadjuvant
therapy and initial tumoral markers’ status on survival we
noticed that patients with tumor downstaging, nodal down-
staging, loco-regional response or normal initial CEA level
had better OS and PFS. Those with tumor downstaging or
normal initial CA 19.9 tumoral marker levels had a higher
LRC. The majority of these results are consistent with the
literature. In our study, pCR did not have any impact on
survival. The low number of patients who actually had pCR
might explain this lack of evidence, described in numerous
studies.The most recent published article35 evaluating the long-
term outcome in patients with a pCR after CT + RT for
rectal cancer concluded that patients with pCR have better54 – 15
long-term outcome than those without it. They stated that
pCR might be indicative of a prognostically favorable biological
tumor proﬁle with less propensity for local or distant recur-
rence and improved survival.
The Gastro-Intestinal Working Group of the Italian Asso-
ciation of Radiation Oncology analyzed retrospectively 566
patients with LARC achieving pCR after neoadjuvant therapy
and they veriﬁed that this favorable group of patients had a
very low rate of local recurrence (1.2%) and a favorable clinical
outcome independent of the neoadjuvant CT schedule used,
achieving a 5-year PFS of 84.7% and 5-year OS of 91.6%. In
such a group of patients, the use of postoperative CT could be
very debatable. Conversely, the subset of patients older than
60 years, with cStage III and treated with a radiation dose of
45 Gy or less experienced a relatively worse prognosis, even
after achieving ypCR. The prognosis of the high-risk group
of patients compares with the outcome of a non-selected
population.20
Conde et al.36 also found a better PFS in those patients
who had pCR (100% vs. 62%, p = 0.023). When consider-
ing only those patients cT3-4 who had downstaging to
ypT0-2, they found a signiﬁcantly better LRC (100% vs. 89,
p = 0.027), PFS (88% vs. 43%, p = 0.003) and OS (89% vs. 77%,
p = 0.048).
Kim et al.37 also showed excellent oncologic outcomes in
patients with pCR, with the pathologic N stage being the most
important factor for oncologic outcomes. Another study18 has
also veriﬁed that pCR or intermediate response was related to
an improved PFS after CT + RT. García-Aguilar et al. analyzed a
group of 168 patients treated with CT + RT and showed a 5-year
LRC of 95%, OS of 68% and a PFS of 95.2% in patients who  had
pCR and 55.4% in patients without pCR. Their study suggested
that a pCR to CT + RT is a favorable prognostic factor in patients
with LARC.19
Valentini et al.32 demonstrated that, after preoperative
CT + RT, clinical response and tumor and nodal pathologic
downstaging have a close correlation with improved outcome.
Indeed, patients with tumor downstaging had a 5-year local
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4. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidalreports of practical oncology an
ontrol of 87.8%, a PFS of 73.1% and an OS of 82.9%, while
hose who  had not tumor downstaging had a local control of
0.5%, a PFS of 47.2% and an OS of 60.9%. Those patients with
odal downstaging also had better 5-year local control (84.3%),
FS (67.1%) and OS (74.3%) than those who  did not have nodal
ownstaging (72%, 42.2% and 56.1%, respectively).
On the other hand, Pucciarelli et al. did not ﬁnd statis-
ically signiﬁcant differences for PFS and OS on comparing
he actuarial survival curves of patients with different tumor
esponses to preoperative treatment, whether evaluated as
umor regression grade or as pTNM stage.38
Sauer et al. conducted a randomized trial comparing preop-
rative vs. postoperative CT + RT, and in the preoperative group
-year OS was 76% and LRC 94%.3 These results are similar to
hose found in our study, where the LRC was 95.6%, the global
-year PFS was 70.3% and OS was 74.2%.
Comparing our results with the single randomized phase III
rial8 that compared 5-FU vs. oral ﬂuoropyrimidine, we  noticed
hat 3-year OS (87% vs. 74%) and LRC (92.5% vs. 91.1%) were
imilar to those of Groups B and A in our study (83.5% vs. 87.6%
nd 97.6% vs. 94.7%, respectively), although slightly higher in
ur study.
Fernandez-Martos et al. studied preoperative CT + RT with
FT and the actuarial rate of 3-year PFS was 72% and OS
as 75%. PFS was 92% for downstaging patients and 51%
or patients who  did not respond (p < 0.00001). OS was sig-
iﬁcantly higher (p = 0.002) for patients with downstaging
ollowing preoperative treatment than for patients who did
ot respond.14
In our study, we  also analyzed the impact of the type
f neoadjuvant therapy on survival in those patients who
ad some kind of treatment response and veriﬁed that those
ith loco-regional response (p = 0.05) and tumor downstaging
p = 0.039) treated with oral CT + RT had a signiﬁcantly better
S, and there was also a trend to higher OS on those patients
ith nodal downstaging (p = 0.090).
There are still insufﬁcient data on adjuvant postoperative
hemotherapy after preoperative treatment with chemora-
iation to allow us to draw a conclusion about its use.39,40
 recent study showed that adjuvant CT was still of bor-
erline signiﬁcance (worse for adjuvant CT).20 In the EORTC
2921 trial postoperative chemotherapy had a non-signiﬁcant
nﬂuence on local relapse and relapse free and overall
urvival. Exploratory subgroup analyses suggest that only
ood-prognosis patients with downstaging of cT3-4 to ypT0-2
eneﬁt from adjuvant CT, with better PFS and OS.21 They con-
luded it was not because tumor downstaging was achieved
hat those patients also beneﬁted from further CT, but rather
hat the same patients who achieved downstaging had a dis-
ase which was responsive for both preoperative and adjuvant
reatment. Those data support those found in other trials as
he QUASAR trial that showed a signiﬁcant beneﬁt on survival
f 3–6%.41
In our study, the addition of adjuvant CT to the patients
cheduled for neoadjuvant CT + RT did not bring a beneﬁt on
-year LRC (96.5% vs. 94%, p = 0.433), on 5-year PFS (70.1% vs.
5.9%, p = 0.188) nor on 5-year OS (71.4% vs. 75.5%, p = 0.749).
owever, if we take into account only those patients who had
oco-regional response, there was a beneﬁt on 5-year PFS in
hose whom received adjuvant CT (81.7% vs. 67.6%, p = 0.05).iotherapy 1 8 ( 2 0 1 3 ) 67–75 73
In subgroup analyses, only considering those patients who
had pathologic downstaging to ypT0-2, our results disagree
from those observed in the EORTC trial, once the 5-year OS,
PFS and LRC were identical for those who were submitted or
not to adjuvant CT (p = 0.404, p = 0.554 and p = 1.0, respectively).
For those patients who had no pathologic downstaging (ypT3-
4), the administration of adjuvant CT also did not have any
beneﬁt on 5-year OS, PFS nor on LRC (p = 0.502, p = 0.208 and
p = 0.515, respectively).
In conclusion, although the results of our study are very
promising, we need to take into account that this study is
not a randomized trial and it might have some bias in the
patients’ treatment modality distribution that might inﬂu-
ence some of the results. Nevertheless, we veriﬁed a good
treatment compliance without increased acute toxicity or
post-operative complications in the oral CT + RT group, as well
as a higher nodal downstaging and loco-regional response
in this group. Tumor downstaging, nodal downstaging, loco-
regional response and a normal pretreatment CEA level turned
out to be important prognostic factors in survival of LARC.
Tumor downstaging and a normal pretreatment CA 19.9 level
had an impact on LRC as well. In subgroup analyses, we
also noticed that patients with tumor downstaging and loco-
regional response treated with oral CT + RT had a signiﬁcantly
better OS. Adjuvant CT had no impact on survival nor on LRC
except in those patients with loco-regional response who  had
higher PFS.
Such differences between these groups of patients,
although both are treated with 5-FU either i.v. or in the
oral form, might be due to the pharmacokinetics of both
capecitabine and UFT oral prodrugs that permits to have a
more  elevated and maintained concentrations of 5-FU for a
prolonged period with constant cytotoxic action, thereby lim-
iting tumor regrowth.
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